1. Strongyloides stercoralis colitis in a patient positive for human T-cell leukaemia virus with rheumatoid arthritis during an anti-rheumatic therapy: a case report
- Author
-
Kunihiko Umekita, Akihiko Okayama, Toshihiko Hidaka, Atsuko Kawano, Haruhiko Maruyama, Hiroyuki Minami, Yayoi Hashiba, and Eiji Nagayasu
- Subjects
medicine.medical_specialty ,biology ,business.industry ,Abatacept ,biology.organism_classification ,medicine.disease ,Gastroenterology ,Ulcerative colitis ,Golimumab ,Strongyloides stercoralis ,Strongyloidiasis ,Internal medicine ,Rheumatoid arthritis ,Strongyloides ,medicine ,Colitis ,business ,medicine.drug - Abstract
An elderly woman with rheumatoid arthritis (RA) presented with a chief complaint of abdominal pain and diarrhoea while undergoing treatment with low-dose corticosteroids and abatacept. Endoscopic and histopathological findings revealed manifestations of ulcerative colitis (UC). An intermediate dose of corticosteroids and 5-aminosalicylic acid were administered. Abatacept was discontinued; the anti-TNF biologic, golimumab, was administered for treatment of both RA and UC. However, colitis worsened in response to this therapeutic regimen. Colonoscopy revealed severe mucosal lesions; larvae were detected in samples taken from multiple shallow mucosal ulcers. The patient was diagnosed with Strongyloides stercoralis colitis based on the results of an anti-parasite antibody test and examination of the larval DNA. Furthermore, serology revealed a positive test for antibodies against human T-cell leukaemia virus type 1 (HTLV-1). Immunosuppressive treatment was terminated; ivermectin was administered, which resulted in improvements in colitis symptoms within a few weeks. There are several published reports describing S. stercoralis colitis as a lethal mimic of UC. Corticosteroid and anti-TNF therapies have been reported as among the major risk factors associated with strongyloidiasis in patients with HTLV-1 infection. Therefore, HTLV-1 and Strongyloides infections may be considered in cases of new-onset gastrointestinal symptoms during immunosuppressive therapy, particularly in HTLV-1-endemic regions.
- Published
- 2020
- Full Text
- View/download PDF